Assess end-organ damage in hypereosinophilic syndrome across cardiac, neurologic, pulmonary, GI, and dermatologic systems to stratify treatment urgency with corticosteroids or mepolizumab.
Assess end-organ damage in hypereosinophilic syndrome across cardiac, neurologic, pulmonary, GI, and dermatologic systems to stratify treatment urgency with corticosteroids or mepolizumab
Each component has a specific meaning:
Note: Interpret the hes end organ score result against the thresholds and context described above.
Enter the cardiac, neurologic, pulmonary, GI, dermatologic systems for the scenario you are assessing. Assess end-organ damage in hypereosinophilic syndrome across cardiac, neurologic, pulmonary, GI, and dermatologic systems to stratify treatment urgency with corticosteroids or mepolizumab. Use the hes end organ score result to inform your calculation.